Why the study?
Preclinical nanoprobes have achieved good experimental effects, creating an urgent call to translate these results into clinical trials.
Molecular nanoprobes show promise in preclinical studies for the early detection and targeted treatment of atherosclerosis, warranting translation into clinical trials.
Preclinical nanoprobe effects in atherosclerosis remain experimental; leaves open clinical translation and efficacy trials.
, achieving good experimental effects. Therefore, there is an urgent call to translate these preclinical results for nanoprobes into clinical trials. For this reason, this review aims to give an overview of currently investigated nanoprobes in the context of atherosclerosis, summarize relevant published studies showing applications of different kinds of formulated nanoprobes in early detection and reverse of plaques, discuss recent advances and some limitations thereof, and provide some insights into the development of the new generation of more precise and efficient molecular nanoprobes, with a critical property of specifically targeting early atherosclerosis.
No takes yet. Share an insight, caveat, or question.
Zan et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: